The Biomedical Division of Japan-based PHC Corporation (PHCbi), a subsidiary of PHC Holdings Corporation (PHCHD), has signed an exclusive agreement with MaxCyte, Inc. to distribute the MaxCyte ExPERT platform in Japan.
In Singapore, SciMed (Asia), a subsidiary of PHCHD, separately entered into an exclusive distribution agreement with MaxCyte and launched the ExPERT platform in the country in June. MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialisation of next-generation cell therapeutics.
Under this partnership, PHCbi will offer sales and service support for MaxCyte’s instruments, consumables, and solutions, providing researchers and manufacturers with access to a clinically proven, non-viral cell engineering platform.
MaxCyte’s ExPERT instrument portfolio is the next generation of leading, clinically and commercially validated electroporation technology for complex and scalable cell engineering. By enabling high transfection efficiency and cell viability, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics.
PHCbi will distribute and support the full range of MaxCyte platforms covered under this agreement, including the ExPERT ATx®, ExPERT STx®, ExPERT GTx® and ExPERT VLx® as well as related consumables such as processing assemblies and electroporation buffers. These platforms are used by researchers worldwide and have been referenced in more than 70 clinical programmes as of Q1 2025.
